
Together We Can Take on Typhoid



Most typhoid cases in The Gambia occur in children **younger than 15 years old.** 





**Drug-resistant typhoid strains** are a growing problem regionally and across the globe.



Global data show that multidrug-resistant (MDR) typhoid prevalence has **increased dramatically since 1992**.<sup>2</sup>



While drug-resistant typhoid has not been isolated in The Gambia, it has been **found in other West African countries**, including Ghana.<sup>2</sup>



Diseases such as typhoid can easily cross borders, and as drug-resistant typhoid becomes more common, **it has the potential to spread to The Gambia.** 



Drug-resistant typhoid is more difficult to treat and **forces the use of more expensive and less readily-available** treatment options.



In The Gambia, **20% of the population does not have access to basic drinking water services**, and 53% lack access to basic sanitation services.<sup>3</sup> This can cause an increase in typhoid risks in Gambia.

## Typhoid conjugate vaccines (TCVs) in The Gambia

The World Health Organization (WHO) recommends the introduction of prequalified TCVs be prioritized in countries with a high burden of typhoid disease or a high burden of drug-resistant typhoid. Support for introduction from Gavi, the Vaccine Alliance is available now. TCVs:



Are highly effective and safe for children as young as **6 months** of age;

Require a **single dose** to prevent 79-85% of typhoid cases in children;<sup>4</sup>



Offer strong protection for **at least 4 years**; and



Can be **co-administered** with measles-rubella, yellow fever, and meningococcal A conjugate vaccines.<sup>5,6</sup>

Findings from an economic analysis predict that, even in the absence of a Gavi subsidy, **a catch-up campaign with TCV could be** cost-effective in The Gambia.<sup>7</sup>

## Let's Take on Typhoid in The Gambia

- Typhoid is endemic in The Gambia, with more than **2,500** cases per year.
- The Gambia's burden of typhoid is most heavily borne by children **younger than 15** years of age.
- Data show a global increase in *drug-resistant typhoid*, which could spread to The Gambia.
- **TCVs** are safe, effective, and WHO-recommended for routine immunization as part of a costeffective, integrated approach to typhoid prevention and control alongside safe water, sanitation, and hygiene interventions.

*Gavi support* for TCV introduction is available *now*.

- 1. Institute for Health Metrics and Evaluation. Global Burden of Disease. 2019. Accessed via: ghdx.healthdata.org/gbd-results-tool.
- 2. Park SE, Pham DT, Boinett C, et al. The phylogeography and incidence of multi-drug resistant typhoid fever in sub-Saharan Africa. Nature Communications. 2018;9(1):509
- 3. Sustainable Development Report. The Gambia. 2020. Available at: https://dashboards.sdgindex.org/profiles/gambia-the/indicators.
- 4. Patel PD, Patel P, Liang Y, et al. Safety and efficacy of a typhoid conjugate vaccine in Malawian children. New England Journal of Medicine. 2021;385(12):1104-1115.
- 5. Sirima SB, Ouedraogo A, Barry N, et al. Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso. International Journal of Infectious Diseases. 2021;102:517-526.
- 6. Sirima SB, Ouedraogo A, Barry N, et al. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial. International Journal of Infectious Diseases. 2021;108:465-472.
- 7. Bilcke J, Antillón M, Pieters Z, et al. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: A modelling study. Lancet Infectious Disease. 2019;19(7):728-739



